Abstract

Objective: The aim of this study was to investigate whether the use of statins was associated with esophageal cancer risk.Methods: A population-based case-control study was conducted in Taiwan. Cases consisted of all patients who were aged 50 years and older and had a first-time diagnosis of esophageal cancer for the period between 2004 and 2010. The controls were matched to cases by age, sex and index date. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by using multiple logistic regression.Results: A total of 197 esophageal cancer cases and 788 controls were examined. The unadjusted ORs for any statin prescription was 0.86 (95% CI = 0.56 – 1.34) and the adjusted OR was 0.96 (95% CI = 0.59 – 1.58). Compared with no use of statins, the adjusted ORs were 0.77 (95% CI = 0.39 – 1.55) for the group having been prescribed statins with cumulative defined daily dose (DDDs) below 115 and 1.16 (95% CI = 0.63 – 2.14) for the group with cumulative statin use of 115 DDDs or more.Conclusions: The present data do not provide evidence to support either beneficial or harmful associations between statin use and esophageal cancer risk.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call